IMUGENE LIMITED — Capital/Financing Update 2014

May 26, 2014

==> picture [152 x 31] intentionally omitted <==

Imugene Appoints Bachem to Manufacture Peptide in Imugene’s HER-2+ Cancer Vaccine

Melbourne, 27 May 2014: Australian immuno-oncology company Imugene Limited (ASX:IMU) has appointed Bachem AG to undertake clinical-grade manufacture of the peptide component of its proprietary therapeutic HER-2+ cancer vaccine HER-Vaxx.

Bachem has extensive experience in synthesising clinical grade peptides suitable for incorporation and assembly into the vaccine delivery platform to be used in HER-Vaxx, and has previously manufactured the peptides (three individual peptide B-cell epitope antigens) used in the completed Phase 1 breast cancer trial. All three peptides are being combined into a single (longer) version of peptide, which could potentially result in manufacturing challenges.

Bachem has now completed a successful feasibility for this longer peptide, and hence manufacture of the vaccine has now commenced.

HER-Vaxx is a proprietary therapeutic cancer vaccine that stimulates a polyclonal antibody response to HER-2/neu, the same biomarker targeted by the US$6.9 billion per annum drug Herceptin®. HERVaxx has successfully completed a Phase 1 study in breast cancer and the next stage of development will be a Phase 2 study in gastric cancer.

Dr Nick Ede, Executive Director Imugene said, "Over my 25 years in the global peptide community from both the scientific and business perspective, Bachem has been a constant in quality and experience. Given Bachem’s experience in supplying peptides in the form suitable for our vaccine delivery platform, this is a logical choice for the manufacture our clinical grade peptide.”

-ends

Contact :

Paul A Hopper Executive Chairman +1 858 334 5820 (US) +61 406 671 515 (Australia) receptogen[at]earthlink.net

Dr Nick Ede Executive Director +61 400 642 254 nede[at]imugene.com

Media contact: Rudi Michelson Monsoon Communications +61 3 9620 3333 rudim[at]monsoon.com.au

About Imugene: Imugene (ASX; IMU) is an immuno-oncology focused biopharmaceutical company developing HER2 +ve gastric and breast cancer vaccines. The Company’s lead product is HER-Vaxx, a proprietary HER2 +ve cancer vaccine that stimulates a polyclonal antibody response to HER-2/neu.

Imugene Limited A.C.N: 009 179 551 Suite 1, 1233 High Street, Armadale, VIC, 3142 Phone: 03 9824 5254 Fax: 03 9822 7735

HER-2/neu is a known and validated receptor over-expressed on various tumours including gastric, breast, ovarian and pancreatic cancers. HER-Vaxx has successfully completed a Phase I study in breast cancer and the next stage of development will be a Phase II study in gastric cancer. Imugene’s corporate headquarters are located in Melbourne, Australia with the scientific team in Vienna, Austria. For more information on Imugene, please visit www.imugene.com

Imugene Limited A.C.N: 009 179 551 Suite 1, 1233 High Street, Armadale, VIC, 3142 Phone: 03 9824 5254 Fax: 03 9822 7735